行情

BLRX

BLRX

BioLine RX
NASDAQ

实时行情|Nasdaq Last Sale

2.670
0.000
0.00%
盘后: 2.660 -0.01 -0.37% 19:49 09/17 EDT
开盘
2.680
昨收
2.670
最高
2.700
最低
2.620
成交量
16.93万
成交额
--
52周最高
6.34
52周最低
1.400
市值
1.26亿
市盈率(TTM)
-2.1760
分时
5日
1月
3月
1年
5年
BioLineRx 计划美国存托股票发行
MT Newswires · 09/03 17:01
BioLine Rx Q2 EPS $(0.01) 超过 $(0.15) 估计
BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.15) by 93.33 percent. This is a 66.67 percent increase over losses of $(0.03) per share from the
Benzinga · 08/18 11:07
BioLineRx 报告 2021 年第二季度财务业绩并提供公司更新
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended and provides a corporate update.
PR Newswire - PRF · 08/18 11:00
预计 2021 年 8 月 18 日的收益
  Companies Reporting Before The Bell • Digital Ally (NASDAQ:DGLY) is likely to report quarterly loss at $0.04 per share on revenue of $2.70 million.
Benzinga · 08/18 09:34
周三开盘前的显着收益
ADI,OTCPK:AWLCF,BLRX,DGLY,DQ,EAT,LITE,LOW,NNDM,PLCE,SFL,TGT,TJX,VIPS,WB,ZIM For Seeking Alpha's full earnings season calendar, click here.
Seekingalpha · 08/17 15:47
BioLineRx 将于 2021 年 8 月 18 日报告 2021 年第二季度的结果
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended June 30, 2021 on Wednesday, August 18, 2021, before the U...
PR Newswire · 08/12 13:30
12 只医疗保健股在周五的盘后交易中移动
Gainers Delcath Systems (NASDAQ:DCTH) stock increased by 8.87% to $11.9 during Friday's after-market session. This security traded at a volume of 379 shares come close, making up 0.45% of its average volume over the last 100 days. The company's market cap...
Benzinga · 07/09 21:20
12 只医疗保健股在周二的盘后交易时段内移动
Gainers
Benzinga · 07/06 20:31
更多
财务预测
实际值（美元）
预测值（美元）
利润表更多
净利润（美元）
同比（%）
资产负债表更多
总资产（美元）
总负债（美元）
资产负债率（%）
现金流表更多
经营现金流（美元）
同比（%）
了解BLRX最新的财务预测，通过BLRX每股收益，每股净资产，每股现金流等数据分析BioLine RX近期的经营情况，然后做出明智的投资选择。
分析师评级

2位分析师的综合评级

强力推荐

免责声明：分析师观点仅供投资者决策参考，不构成任何买卖投资建议。

目标价格预测
分析师预测BLRX价格均价为14.50，最高价位19.00，最低价为10.00。
EPS
机构持股
总机构数: 49
机构持股: 166.47万
持股比例: 3.52%
总股本: 4,727.47万
类型机构数股数
增持
2
30.69万
建仓
7
11.50万
减持
8
67.05万
平仓
6
316.45万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+0.49%
制药与医学研究
-0.10%
高管信息
Chairman/Director
Aharon Schwartz
Chief Executive Officer
Philip Serlin
Chief Financial Officer
Mali Zeevi
Vice President
Ella Sorani
Chief Scientific Officer
Merril Gersten
Vice President
Moshe Phillip
Vice President
Abi Vainstein-Haras
Vice President - Business Development
Hillit Mannor Shachar
Vice President - Business Development
David Malek
Director
Michael Anghel
Director
Barbara-Jean Bormann
General Manager
Leah Klapper
Director
Raphael Hofstein
Director
Sandra Panem
Non-Executive Director
Nurit Benjamini
Director
Jacob Friedman
暂无数据
  • 全部
  • 财务报告
  • 内部人交易
更多
BLRX 简况
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

微牛提供BioLine RX Ltd(NASDAQ-BLRX)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的BLRX股票新闻，以帮助您做出投资决策。

模拟交易：模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易BLRX股票基本功能。